Octanate (Human Coagulation Factor Viii)

Octanate is a factor VIII concentrate used in the management of bleeding disorders that involve the intrinsic coagulation pathway.

• Hemophilia A (severe): provides replacement of deficient factor VIII to prevent or control spontaneous and traumatic bleeding.
• Hemophilia A (moderate to mild): raises factor levels to reduce bleeding frequency and severity.
• Acquired hemophilia A: supplies exogenous factor VIII to counteract auto‑antibody mediated deficiency.
• Peri‑operative management: ensures adequate hemostasis during surgical procedures in patients with factor VIII deficiency.

• Octanate supplies functional human factor VIII, a cofactor that binds activated factor IX on phospholipid surfaces, accelerating the conversion of factor X to Xa within the intrinsic tenase complex. This restores the cascade that generates thrombin, leading to fibrin clot formation and hemostasis.

Octanate may be associated with adverse reactions following infusion.

Common Side Effects

• Infusion‑related reactions: fever, chills, headache, nausea, arthralgia, fatigue.
• Local site discomfort at the injection site.
• Transient elevations in liver enzymes.

Serious or Rare Side Effects

• Development of neutralizing inhibitors (antibodies) against factor VIII.
• Anaphylaxis or severe hypersensitivity reactions.
• Thrombotic events, including deep vein thrombosis.
• Transmission of viral pathogens (theoretical risk).

Octanate requires careful monitoring to ensure safety and efficacy.

• Allergic reactions: observe patients for signs of hypersensitivity during and after infusion.
• Inhibitor development: test for neutralizing antibodies regularly, especially in previously untreated patients.
• Bleeding risk: adjust dosing based on clinical response and factor VIII activity levels.
• Surgical procedures: confirm adequate factor levels before any invasive intervention.
• Pregnancy and lactation: use only if the potential benefit justifies the potential risk to the fetus or infant.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Octanate may interact with other hemostatic agents, affecting coagulation balance.

Major Interactions (Avoid)

• Activated prothrombin complex concentrates (aPCC): increased risk of thrombosis when combined with factor VIII.
• High‑dose antifibrinolytics (e.g., tranexamic acid) in patients with a history of thromboembolic disease.

Moderate Interactions (Monitor Closely)

• Other factor concentrates (e.g., factor IX): monitor for additive clotting effects.
• Immunosuppressive therapies: may influence inhibitor development.
• Vaccines administered concurrently: observe for enhanced immune response.